1.31 USD
▼-0.06-4.38%
盘后 1.53 0.00%
2026-09-15
市值
$828.79M
市盈率
—
EPS
-0.10
股息率
—
52 周区间
1.04 – 2.01
成交量
16.49M
Beta
0.61
目标价
4.25
52W 低 1.0452W 高 2.01
价格走势
公司简介
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini...